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Summary 
Objectives: This study aimed to examine changes to the microbiota composition and 
metabolic profiles of seven patients with recurrent Clostridium difficile infection 
(rCDI), following treatment with faecal microbiota transplant (FMT). 
Methods: 16S rDNA sequencing and 1H NMR were performed on faecal samples 
from the patients (pre-, post-FMT, and follow-up) and the associated donor samples. 
Sparse partial-least-square analysis was used to identify correlations between the 
two datasets. 
Results: The patients‟ microbiota post-FMT tended to shift towards the donor 
microbiota, specifically through proportional increases of Bacteroides, Blautia, and 
Ruminococcus, and proportional decreases of Enterococcus, Escherichia, and 
Klebsiella. However, although cured of infection, one patient, who suffers from 
chronic alcohol abuse, retained the compositional characteristics of the pre-FMT 
microbiota. Following FMT, increased levels of short-chain fatty acids, particularly 
butyrate and acetate, were observed in all patients. Sparse partial-least-square 
analysis confirmed a positive correlation between butyrate and Bacteroides, Blautia, 
and Ruminococcus, with a negative correlation between butyrate and Klebsiella and 
Enterococcus. 
Conclusions: Clear differences were observed in the microbiota composition and 
metabolic profiles between donors and rCDI patients, which were largely resolved in 
patients following FMT. Increased levels of butyrate appear to be a factor associated 
with resolution of rCDI. 
 
Keywords: Clostridium difficile; Faecal microbiota transplantation; Metataxonomics; 
Metabonomics; Alcohol abuse; Sparse partial-least-square analysis. 
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Introduction 
Although Clostridium difficile is present in the intestines of ~3-5% of healthy adults,1 
the occurrence of C. difficile infection (CDI) in healthy individuals is relatively 
uncommon due to the protective effect of the gut microbiota. The incidents and 
severity of CDI has risen significantly over the last decade, and it is now recognised 
as the main causative agent of healthcare-associated infectious diarrhoea in 
hospitals worldwide.2 The standard treatment for CDI is the administration of 
metronidazole for mild to moderate infections, and oral vancomycin or fidaxomicin for 
severe infections and relapses. The ability of C. difficile to form spores, coupled with 
the increase in antibiotic-resistant strains, can lead to persistence of infection, 
relapses, and the administration of more antibiotics, which further depletes the 
commensal bacteria. This creates an environment that is more favourable to C. 
difficile, thus setting up a cycle of relapse and re-infection. It is estimated that 20-
30% of patients who develop a first episode of CDI go on to have at least one 
relapse, and of these, a further 60% develop further episodes of relapses.3 This 
increases the need for further antibiotics, the risk of antibiotic-resistance in the gut 
commensal flora, and costs to the health service, with each episode of CDI 
estimated to cost approximately £7000 in 2010.4 
Faecal microbiota transplants (FMT) represents an effective alternative to antibiotics 
to treat recurrent CDI (rCDI), with a primary cure rate as high as 91%.5 The central 
tenet behind FMT is that the introduction of a healthy bacterial community into the 
intestines produces an environment that is less favourable to C. difficile by 
increasing colonisation resistance and reinstating a protective effect. The 
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advantages of this treatment are that it is quick, cost-effective, and could help to 
eradicate antibiotic resistant strains of C. difficile.  
It is known that a dysbiotic gut microbiota increases the risk of developing CDI, 
however whether there is a common element within this community composition that 
could help to determine if a patient is at greater risk of rCDI is as yet unknown. The 
reduction in diversity within the dysbiotic gut microbiota would also suggest a 
reduction in metabolic potential through the loss of gene diversity. The functional 
redundancy6 within the gut microbiota suggests, that metabolic function is more 
relevant than which species are present or absent. Whilst a number of studies have 
looked at the changes in microbiota composition due to FMT,7-10 we know little about 
the changes to the metabolic capacities of the altered microbiota. The aim of this 
study was to assess FMT-induced changes in both the microbial community 
structure and metabolite profiles of the gut microbiomes of seven patients with rCDI, 
as well as those of their associated FMT donors.  
 
Patients and methods 
Patients 
Patients were selected as candidates for the FMT procedure if they had at least two 
confirmed recurrences of CDI. C. difficile testing was based on a two stage algorithm 
in line with Public Health England recommendations.11 This involves screening 
faecal samples by glutamate dehydrogenase enzyme immunoassay (Techlab, USA), 
followed by C. difficile toxin testing by enzyme immunoassay (Techlab, USA). 
Glutamate dehydrogenase positive, toxin negative samples were further tested for 
the presence of toxigenic genes by PCR. FMT exclusion criteria included 
immunocompromised patients, those aged less than 16, and those with severe 
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comorbidities which would make the patient unfit for endoscopy. FMT was 
introduced into clinical care at Norfolk and Norwich University Hospital following 
approval by the New Therapies committee, and was performed in accordance with 
the Helsinki Declaration of 1975. Patients were consented for the study by a clinician 
following a detailed discussion of the procedure with the patient or their next of kin. 
All patient data is fully anonymised. 
 
Donor screening 
The faecal donors used for the cohort of patients who underwent FMT in this study 
were both healthy Caucasian males with a BMI between 24-27 kg/m2, aged 36 (D05) 
and 30 (D03) years of age, respectively. Potential donors were asked to complete a 
questionnaire adapted from van Nood et al12 regarding their medical history and 
lifestyle habits to identify risk factors for potentially transmittable diseases. Eligible 
candidates provided blood and stool samples for laboratory screening tests. Blood 
samples were screened for hepatitis A, B, C, and E antibodies, HIV 1 & 2, human T-
lymphotropic virus 1 & 2, Epstein-Barr virus, Cytomegalovirus, syphilis, Entamoeba 
histolytica, Strongyloides stercoralis, and Treponema pallidum. Stool samples were 
tested for the presence of C. difficile or its toxins, Helicobacter pylori antigen, 
Norovirus, methicillin-resistant Staphylococcus aureus, vancomycin-resistant 
enterococci, extended-spectrum β-lactamase-producing organisms, 
carbapenemase-producing Enterobacteriaceae, Escherichia coli O157, Salmonella 
spp., Shigella spp., and Campylobacter species. In addition, microscopy was used to 
investigate for ova, cysts, and parasites. Prior to the donation of stool samples for 
each FMT procedure, donors were asked to refrain from eating peanuts and 
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shellfish, and to complete a short screening questionnaire to confirm no changes to 
health or lifestyle since the last donor screening that may put the patient at risk. 
 
Faecal suspension preparation 
Donor faeces were collected in a sterile container on the day of the procedure, and 
transferred to a sterilised class II safety cabinet (Walker Ltd, UK). A maximum of 80 
g of donor stool was homogenised with sterile saline (0.9%), to a ratio of 5 ml saline 
per gram of stool, in a strainer bag (BA6141/STR; Seward Limited, UK) using a 
Stomacher® 400 Circulator (Seward Limited, UK) set to 230 RPM for a duration of 1 
minute. The filtered faecal preparation was drawn up into labelled sterile 60 ml 
syringes using nasojejunal tubing connected to the Luer lock. The syringes were 
secured with sterile Luer lock caps and transported immediately to the hospital. 
Aliquots of the donor faecal sample were immediately stored at -20 ˚C until analysis. 
 
Faecal suspension infusion 
Patients were prescribed oral vancomycin 500 mg four times daily for 4 days, with 
the last dose received the night before the procedure. Also, on the day before the 
FMT procedure, a bowel lavage is performed using 4 litres of macrogol solution 
(Klean-Prep, Norgine). Patients were taken to the endoscopy unit for insertion of 
nasojejunal tube the night before the procedure. Our FMT protocol was adapted from 
that of van Nood et al.12 On the day of FMT infusion, the patient‟s headrest was 
elevated to 45 degrees, patency of the nasojejunal tube was checked by flushing 
with water, and 420 ml of faecal suspension was delivered slowly by the patient‟s 
bedside in the isolation room via a nasojejunal tube using the prefilled syringes. This 
was performed at a rate of ~20 ml per minute with a break of 5-10 minutes applied 
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halfway through the procedure. Post-infusion instructions were to monitor 
observations, and record bowel motions. Patients could take on fluids one hour after 
the procedure, and were observed overnight before discharge the next day at the 
earliest. Although there are no agreed durations of follow-up post-FMT,13 van Nood 
et al12 used two endpoints to measure cure, namely no relapse after 5 weeks, and no 
relapse after 10 weeks. Resolution was defined as type 4 or less on the Bristol stool 
chart or stool normal for the patient e.g. in case of percutaneous endoscopic 
gastrostomy feeding. We followed patients up by telephone or in person if they were 
re-admitted into the hospital for an unrelated illness. Post-FMT samples were 
collected after a minimum of 10 days post-FMT, and postal kits were provided to 
patients who were willing to donate a „follow-up‟ sample up to 2 weeks later. 
 
Sample analysis 
Faecal microbiota analysis 
Faecal samples were collected from recipients within 9 days prior to FMT, however 
the pre-FMT sample for patient R13 was not collected within this timeframe, and a 
previously frozen sample obtained whilst the patient was suffering from the same 
episode of CDI was used. Further samples were collected for all recipients following 
the procedure („post-FMT‟ range: 11-141 days; „follow-up‟ range: 4-14 days after 
post-FMT sample), and stored at -20 ˚C until analysis. The DNA was extracted using 
the FastDNA SPIN Kit for Soil (MP Biomedicals, UK) with a bead-beating step.14 
DNA yield was quantified using the Qubit fluorometer prior to the samples being sent 
to the Earlham Institute (UK), where the V4 hypervariable region of the 16S rRNA 
genes were amplified using the 515F and 806R primers with built-in degeneracy.15 
The amplicons were sequenced using paired-end Illumina sequencing (2 x 250 bp) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
on the MiSeq platform (Illumina, USA). Sequencing data, for the 21 samples that had 
an appropriate level of sequencing depth, were analysed using the Quantitative 
Insights Into Microbial Ecology (QIIME) 1.9 software and RDP classifier 16S rRNA 
gene sequence database.16, 17 The trimmed reads were filtered for chimeric 
sequences using ChimeraSlayer, bacterial taxonomy assignment with a confidence 
value threshold of 50% was performed with the RDP classifier (version 2.10), and 
trimmed reads clustered into operational taxonomic units at 97% identity level. Alpha 
diversity and rarefaction plots were computed using the Chao1 index. Weighted and 
unweighted UniFrac distances were used to generate beta diversity principal 
coordinates analysis plots, which were visualised using the Emperor tool. 
 
Faecal metabolite analysis 
A known mass (~ 100 mg) of thawed faecal samples were added to sterile tubes. 
The faecal waters were generated by adding the phosphate buffer (prepared in D2O) 
to 8.3% w/v. Homogenised faecal waters were centrifuged at 16,200 x g at room 
temperature for 5 min. The supernatants were filter sterilised (0.2 μm) and placed in 
a 5 mm NMR tube. The 1H NMR spectra were recorded at 600 MHz on a Bruker 
Avance spectrometer (Bruker BioSpin GmbH, Germany) running Topspin 2.0 
software and fitted with a cryoprobe and a 60-slot autosampler. Each 1H NMR 
spectrum was acquired with 1280 scans, a spectral width of 12,300 Hz, and an 
acquisition time of 2.67 seconds. The “noesypr1d” pre-saturation sequence was 
used to suppress the residual water signal with a low-power selective irradiation at 
the water frequency during the recycle delay and a mixing time of 10 ms. Spectra 
were transformed with a 0.3 Hz line broadening, and were manually phased, 
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baseline corrected, and referenced by setting the TSP methyl signal to 0 ppm. The 
metabolites were quantified using the software Chenomx® NMR Suite 7.0TM. 
 
Statistical analysis 
Data for groups were expressed as mean ± standard deviation, with the exception of 
the microbiome relative abundance data, which is expressed as median ± standard 
deviation. Statistical comparisons of the alpha diversity measurements were 
performed using one-way analysis of variance followed by Tukey‟s Multiple 
Comparison post-test with an alpha value of 0.05. Multivariate statistical analysis 
(principal component analysis) of the 1H NMR data was carried out using the PLS 
Toolbox v5.5 (Eigenvector Research Inc.,Wenatchee, WA) running within Matlab 
v7.6 (The MathWorks Inc., Natick, MA). Autoscaling was applied to the variates. 
1H NMR and sequencing datasets (the former comprising 100 metabolites and the 
latter the relative abundance of 271 bacterial taxa, for the same 21 samples) were 
also analysed jointly. Firstly, the two blocks of data were analysed by canonical 
correlation analysis (CCA), using the sPLS variant to cope with mathematical issues 
arising from the data being high-dimensional.18 This analysis defines latent variables, 
or canonical axes, for each of the NMR and sequencing blocks of data; the data is 
then summarised by the position of the samples (scores) on these axes. The sample 
scores on corresponding pairs of canonical axes reflected the overall strength of the 
relationship between the two blocks of data. The original variables (NMR and 
sequencing) were then simultaneously displayed on „correlation circle plots‟, in which 
the correlation between each variable and each canonical axis is projected.19 This 
revealed possible correlations which were further explored by calculating the 
Pearson correlation coefficient between each bacterial taxa and each of the 
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metabolites measured by 1H NMR. CCA was carried out using the R (v3.3.3) 
package mixOmics v6.1.2, and correlation coefficient maps produced in Matlab v9.1 
(The MathWorks Inc., Natick, MA). Prior to CCA and calculation of the correlation 
coefficient, the sequencing data were subjected to the centered log-ratio 
transformation to avoid spurious results.20-22 
 
 
Results 
Patient demographics 
Seven patients with rCDI were given FMT at the Norfolk and Norwich University 
Hospital. Metagenomic and metabonomic analyses were performed on stool 
samples collected before and after the FMT procedure, along with the associated 
donor stool samples. Patient demographics are shown in Table 1. 
 
16S rRNA gene sequencing analysis 
Faecal microbiota composition 
The sequencing data generated 1,627,111 high-quality reads, with an average of 
77,481 ± 10,888 reads per sample, which clustered into 9,818 operational taxonomic 
units at 97% identity. Diversity analyses were rarefied to 63,159 sequences per 
sample to match the lowest number of sequences obtained for a sample, and 
therefore avoid bias. The metataxonomic data (Supplemental figures 1 & 2) indicated 
that although the microbiota of many of the patients resembled more closely that of 
the donor microbiota following FMT (Figures 1A & 2A), the microbiota alteration in 
patient R44 did not follow this trend (Figures 1B & 2B). It transpired that this patient 
suffers from chronic alcohol abuse, and this may have greatly affected the ability of 
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the donor microbiota to successfully colonise this recipient‟s gastrointestinal tract. 
The results in Table 2 indicate that following FMT, there was a general trend towards 
an increase in members of the Bacteroidetes (pre-FMT 1.1%, post-FMT 6.5%, 
follow-up 12.4%), an initial decrease of Firmicutes (pre-FMT 57.8%, post-FMT 
50.3%, follow-up 61.5%), and limited change in the relative proportions of 
Proteobacteria (pre-FMT 13.9%, post-FMT 16.3%, follow-up 3.6%). Comparison of 
the metataxonomic data at the genus level suggests an increase in the relative 
proportions of Bacteroides (pre-FMT 0.4%, post-FMT 4.6%, follow-up 9.6%), Blautia 
(pre-FMT 0.2%, post-FMT 3%, follow-up 7.3%), and members of Ruminococcus of 
the Lachnospiraceae family (pre-FMT 1.6%, post-FMT 4.9%, follow-up 11.1%). In 
contrast, the relative proportions of Enterococcus (pre-FMT 11.3%, post-FMT 1.1%, 
follow-up 0.4%), and Escherichia (pre-FMT 5.1%, post-FMT 3.5%, follow-up 1.1%) 
decreased after treatment. However, although cured of CDI, it is interesting to note 
that these data were skewed by the inclusion of the post-FMT sample obtained from 
patient R44. Omission of patient R44 samples significantly impacted on the median 
relative proportions of Proteobacteria (post-FMT 1.5% vs 16.3%), and Klebsiella 
(post-FMT 0.2% vs 0.02%). 
 
Faecal microbiota diversity analyses 
Alpha diversity analysis using the Chao1 index (Figure 3), and one-way ANOVA with 
Tukey‟s multiple comparisons test, indicated a significant reduction in bacterial 
diversity in the pre-FMT samples, compared to the donor samples (P = 0.0091). 
Although bacterial diversity was observed to increase following the FMT procedure, 
this was not statistically significantly different to the diversity within the pre-FMT 
samples. However, neither the post-FMT nor the follow-up samples were 
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significantly different from the donor samples, indicating an increase in bacterial 
diversity following FMT. Weighted beta diversity analysis indicated a clear separation 
between samples obtained from donors, which clustered to the right of the principle 
coordinates analysis plot, and those from recipients prior to FMT, which were located 
on the left side of the plot (Figure 4). In addition, it indicates that the faecal 
microbiota of R42, R05, and R23 were modified by the FMT procedure to closely 
resemble that of the healthy donors. 
 
Faecal metabolite profile 
A total of 22 samples obtained from 2 donors (n = 5) and 7 patients (pre-FMT n = 7, 
post-FMT n = 7, and follow-up samples n = 3) were prepared, 1H NMR spectra 
recorded, and signals carefully characterised using information from 2-dimensional 
NMR experiments, such as HSQC, HMBC, and COSY, the literature data,23-25 and 
the human metabolome database. A specialised Chenomx software® was used to 
quantify 100 different metabolites in an absolute manner (Table 3). 
Donor profiles were characterised by relatively high levels of butyrate, propionate, 
acetate, succinate, glucose, and ethanol (30, 13, 108, 22, 8, and 6 mmol/kg, 
respectively), and lower levels of a diverse range of other metabolites. The presence 
of many compounds was sample-dependant but amino acids, their associated 
products (methylsuccinate, 2-piperidinone, β-alanine, and 5-aminovalerate), phenolic 
compounds (3-(3-hydroxyphenylpropionate), phenylpropionate, and phenylacetate), 
amines (methyl-, dimethyl- and trimethyl-amines, putrescine, cadaverine, and 
tyramine), nucleobases (adenine and uracil), sugars (glucose, arabinose, fucose, 
and ribose), and nicotinate derivates (nicotinate, NAD+, and nicotinamide ribotide) 
were detected in the 1H NMR profiles of the donor samples (Supplemental figure 3). 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
As with the donor‟s profiles, the patient profiles displayed great intra- and inter-
individual variability in the levels of many metabolites. Metabolic profiles of pre-FMT 
patient profiles contained, on average, more uncharacterised signals including those 
of analgesics (6.80, 6.85, and 6.93 ppm), higher levels of amines (dimethylamine, 
cadaverine, putrescine and tyramine), amino acids, branched chain fatty acids 
(BCFAs) (isobutyrate, isocaproate, isovalerate and 2-methylbutyrate), phenol, 
benzoate, and p-cresol, and lower levels of butyrate, alcohols (ethanol and 
methanol), osmolytes (choline), and bile acids (deoxycholate, lithocholate, and 
cholate). 
Using patient R42 as an example of metabolic changes, it was found that butyrate, 
propionate, and acetate levels increased from 1.6, 2.8, and 46.6 mmol/kg, to 18.3, 
26.2, and 110.6 mmol/kg, respectively. Conversely, putrescine, cadaverine, 
tyramine, 1-methylnicotinamide, and some unidentified NMR metabolite signals 
disappeared. A decrease of 3-hydroxybutyrate (from 9.6 mmol/kg to 0.8 mmol/kg) 
was also observed. Glucose levels increased from 0.3 mmol/kg to 12.2 mmol/kg, 
which is within the range observed from samples of the donor associated with patient 
R42. In contrast, there was little improvement in the levels of butyrate, propionate, 
and acetate in the samples from patient R44 (0, 0.8, 14.3 mmol/kg vs 0.2, 3.9, 23.3 
mmol/kg), and although there was a decrease in putrescine levels, the amount of 
cadaverine and tyramine were largely unchanged. Interestingly, increased levels of 
lactate, 1,2-propanediol, glycerol, and glucose were observed in this patient following 
FMT (data not shown). The levels of butyrate (Figure 5) were relatively low in the 
pre-FMT patient samples (5.39 mmol/kg ± 7.46), compared to the donor samples 
(30.25 mmol/kg ± 5.07), and the concentration of butyrate increased in most patients 
following the FMT procedure (average 7.67 mmol/kg ± 6.66). For those patients that 
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provided a further post-FMT sample (follow-up sample; between 23 and 36 days 
after treatment), a higher concentration of faecal butyrate (17.67 mmol/kg ± 11.72) 
was detected compared to pre-FMT levels (Figure 5). The levels of butyrate, acetate, 
and fucose increased post-FMT converging towards those of the donors 
(Supplemental figure 4). Despite this improvement, the levels of butyrate, acetate, 
ethanol, methanol, galactose, arabinose, deoxycholate, lithocholate, and isovalerate 
remained significantly different compared to the donor samples, even after the FMT 
procedure (Table 3). Only the levels of galactose and arabinose significantly differed 
from the donors in the follow-up samples (Table 3). Principal component analysis 
indicated that a positive score on the second principal component (PC) may 
potentially correlate with a healthier metabolic profile, as the scores of all five of the 
donor samples were found in this half of the score plot (Supplemental figure 5). 
Interestingly, some of the patients‟ metabolic profiles (R44, R42, and R23) shifted 
towards the profiles of the donors to varying degrees after the FMT procedure. 
 
Correlation analysis 
The scores obtained by canonical correlation (samples coordinates on the latent 
variables defined for each of the two blocks of data, (Supplemental figure 6)) show 
that there is strong evidence of a relationship between 1H NMR and 16S rRNA gene 
sequencing datasets (r > 0.9 for scores 1 to 10). Furthermore, they highlight the fact 
there are characteristics that are specific to donors and to recipients, as shown on 
the first canonical axis, both in terms of NMR measurements and bacterial taxa. The 
correlation circle plots (which show the correlation between the original variables in 
either the NMR or the 16S rRNA gene sequencing dataset, and their canonical axes) 
indicate which of the original variables contribute most of that, being situated towards 
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the outside edge of the circle corresponding to correlation = 1 on the first canonical 
axis (Supplemental figure 7). Two clusters of variables can be seen on the first axis, 
one with large negative, and the other with large positive coordinates. These two 
sets of variables are expected to be negatively correlated. Moreover, it is expected 
that variables within a cluster will be positively correlated.19 Further examination of 
the map of Pearson correlations between these two clusters of variables confirms 
the high correlations between a number of metabolites and bacterial taxa (Figure 6). 
For instance, butyrate was found to positively correlate to the presence of 
Bacteroides, Blautia, and Ruminococcus, whilst Klebsiella and Enterococcus were 
negatively correlated with butyrate. 
 
 
Discussion 
In this study, we performed gut microbiota community composition and metabonomic 
analyses on the faecal samples of seven patients who underwent FMT to combat r-
CDI. The symptoms associated with CDI were resolved for six of the seven patients, 
and no recurrences of CDI have been reported in the 22 - 27 months following the 
single administrations of FMT. It has been observed that CDI sufferers generally 
have a dysbiotic microbiota, with a larger proportion of Proteobacteria than is 
generally seen in a healthy microbiota.7, 26 Our results based on the 16S rRNA gene 
analysis confirm the higher levels of Proteobacteria in rCDI patient samples before 
FMT. Post treatment there was a general increase in the relative proportions of 
Firmicutes and Bacteroidetes, with a decrease in members of the Proteobacteria as 
has been previously described.7, 26 At a higher resolution, the relative proportions of 
Bacteroides, Blautia, and Ruminococcus from the Lachnospiraceae family increased, 
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whilst Enterococcus and the Proteobacteria Escherichia and Klebsiella decreased, 
which supports the findings of previous studies.8-10, 26, 27 Interestingly these changes 
were not observed in patient R44, whose post-FMT sample, collected 11 days after 
the procedure, continued to resemble a dysbiotic community, and on the contrary, 
the levels of Klebsiella (Proteobacteria) increased from 5.8% to 84.6% 
(Supplemental figure 2) of the total bacterial population. Despite what appears to be 
an adverse effect on the gut microbiota composition, rCDI was resolved, and it is 
possible that the patient microbiota had changed after FMT but over the eleven days 
before a post-FMT sample was collected, a resumption of alcohol abuse had 
reversed this effect. It is known that chronic alcohol use can lead to a dysbiotic 
microbiota, with a predomination of Gammaproteobacteria including Klebsiella 
species, as was observed with patient R44.28-30 Therefore, the long-term success of 
FMT procedures may be influenced by lifestyle, and it could be interesting to explore 
if chronic alcohol abuse increases the susceptibility of individuals to CDI. 
As with some other gastrointestinal diseases, a reduction in the diversity of the 
colonic microbiota is commonly seen in CDI patients.31, 32 Alpha diversity 
measurements (Figure 3) indicated that the donor‟s gut microbiota contained a 
higher species richness than the patients before FMT (P = 0.0091). The 
administration of FMT increased the diversity of patients‟ gut microbiota, and this 
remained stable over time, although this diversity did not reach the levels observed 
in the healthy donors. This is potentially due to the natural decline in bacterial 
diversity that has been reported in the gut microbiota as we age (mean age: FMT 
recipients 71.3 ± 15.9 years; donors 33.0 ± 4.2 years).33, 34 Beta diversity analysis 
(Figure 4), which gives an indication of the similarities or differences between 
samples, shows a clear separation of the donor‟s and pre-FMT patient samples, 
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indicating substantial differences between the microbiota profiles of the two groups. 
As this separation was determined by principal coordinate 1, it suggests that the 
microbiota composition of the two groups represented the greatest variability. After 
treatment, the profiles shift towards the associated donor samples. 
Metabonomic analysis was performed using 1H NMR to observe any differences 
between the metabolic profiles of those suffering CDI and the donors, and whether 
FMT restored these metabolic functions. One hundred metabolites were identified 
and quantified in 22 faecal samples. Principal component analysis suggested that 
the metabolome of some of the patients shifted towards the profiles of the donors to 
varying degrees after FMT (Supplemental figure 5). Coupled with the alleviation of 
symptoms, this change in metabolite profile may reflect a shift towards a healthier 
metabolic state. It is difficult to discern which metabolites, if any, may be associated 
with this improvement, but an increase in the short-chain fatty acids acetate and 
butyrate were observed in most patients. Butyrate has been linked with multiple 
health benefits for the host, such as providing an energy source for colonocytes, 
inhibition of growth and virulence gene expression of pathogens,35, 36 inflammation 
suppression,37, 38 and the direct inhibition of C. difficile growth in vivo.39 In addition, a 
recent study by Fuentes et al40 observed that long-term remission of ulcerative colitis 
following FMT was associated with a restoration of the capacity of the gut microbiota 
to produce butyrate. Acetate offers host mucosal protection and healing 41, 42 by 
modulating host defence 43 and inflammatory responses.44 Using sparse partial-
least-square (sPLS) canonical correlation analysis, it was possible to separate donor 
and patient samples based on microbiota composition and metabolite profile 
(Supplemental figure 6). Furthermore, calculating the Pearson correlation coefficient 
enabled correlations between bacterial taxa and metabolites to be mapped (Figure 
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6). This identified a range of metabolites, including butyrate, which were positively 
correlated with the taxa (Bacteroides, Blautia, and Ruminococcus) that proportionally 
increased following FMT, and negatively correlated with Klebsiella (except for a 
largely neutral correlation to succinate), and Enterococcus, which exhibited 
proportional decreases. Many of the rCDI patients had relatively high levels of 
branched chain fatty acids (BCFAs), phenolic compounds, amino acids, and certain 
amines, compared to the donor samples. In general, the levels of some of these 
metabolites were found to decrease following the FMT procedure, and this may have 
also contributed to the improved health of the patients. Although the majority of FMT 
recipients showed an increase in short-chain fatty acids after treatment, this was not 
observed in patient R44, who suffered from alcoholism. The increased levels of 
lactate and glycerol could be an effect of alcohol abuse following ethanol 
metabolism.45 It has been shown that Klebsiella can metabolise glycerol under 
anaerobic conditions to produce propanediols, which can then be used as an energy 
source for these bacteria.46 As such, the chronic consumption of alcohol could lead 
to a dysregulation of hepatic processes, which may provide increased levels of these 
metabolites that would give bacteria, such as Klebsiella species, a competitive 
advantage over more beneficial bacteria. 
It has previously been shown that chronic alcohol abusers often have increased 
proportions of Gammaproteobacteria in their gut microbiota,29 which is consistent 
with the observations made here. However, further work is required to identify if 
elevated levels of faecal lactate, glycerol, and propanediols are potential biomarkers 
of this disorder. 
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The results of this study confirm the value of FMT as a viable alternative to the use 
of costly antibiotics for the treatment of rCDI. Although the modulation of the 
microbiota composition is considered to play a pivotal role in FMT, the resulting 
metabolic alteration of the gut microbiota should also be considered as an important 
factor in the resolution of rCDI. A larger study is in progress focusing on the 
microbial-based metabolites to identify biomarkers for identification of individuals 
susceptible to CDI based on both microbiota composition and their metabolic 
profiles. 
 
 
Conclusions 
Faecal microbiota transplantation has been shown to be a robust and cost-effective 
method to combat recurrent-Clostridium difficile infection (rCDI), however to increase 
the effectiveness of this treatment it is necessary to elucidate the mechanisms by 
which this works, and factors that may reduce its efficacy. Our results indicate that 
the resolution of rCDI was accompanied by an alteration to the microbiota 
composition towards that of the donor profile to varying degrees, with increased 
diversity that was maintained beyond seven weeks after the FMT procedure. We 
also demonstrated that the shift in bacterial composition also correlated with altered 
functional metabolism of the recipient microbiota, where the metabolic profile again 
shifted towards that of the donor. Correlation analysis enabled the identification of 
strong relationships between bacterial taxa and metabolites, including positive 
correlations between butyrate and taxa that proportionally increased after FMT. 
Finally, lifestyle factors, such as chronic alcohol consumption, could potentially 
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increase a person‟s susceptibility to CDI, and should be considered prior to FMT 
administration. 
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Figure legends 
 
 
Figure 1. Post-FMT profiles resembled the associated donor profile, but this 
was not observed in all recipients. Proportions of bacterial phyla in pre- and post-
FMT samples, as well as the associated donor samples. Bacterial DNA was 
extracted from faecal samples, and the 16S rRNA genes were sequenced using 
paired-end sequencing on an Illumina MiSeq platform. Bioinformatic analysis was 
performed using QIIME 1.9.0 and RDP classifier. 
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Figure 2. Proportions of bacterial genera in faeces of pre- and post-FMT 
patients and the corresponding donors. Bacterial DNA was extracted from faecal 
samples, and the 16S rRNA genes were sequenced using paired-end sequencing on 
an Illumina MiSeq platform. Bioinformatic analysis was performed using QIIME 1.9.0 
and RDP classifier. The key refers to bacterial genera present at >0.5% of the 
population. 
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Figure 3. FMT treatment increased bacterial diversity. Alpha diversity rarefaction 
measures of faecal bacteria before (n = 7) and after FMT treatment (n = 6), follow-up 
samples (n = 3), and associated donor samples (n = 5) were calculated using QIIME 
1.9.0. Data for the post-FMT sample for patient R48 was omitted due to poor 
sequencing depth. Mean ± SD, analysed using one-way ANOVA with Tukey‟s 
multiple comparisons test, and an alpha value of 0.05; ** P = 0.0091.  
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Figure 4. Beta diversity analysis shows a separation of faecal microbiota 
based on health status (pre-FMT vs donor). Weighted beta diversity analysis of 
faecal microbiota samples from patients (pre-FMT (n = 7), post-FMT (n = 6), and 
follow-up samples (n = 3)) and donors (n = 5). Beta diversity analysis was performed 
using the UniFrac metric using QIIME 1.9.0, and visualised as a 3D principal 
coordinates analysis plot using Emperor. Data for the post-FMT sample for patient 
R48 was omitted due to poor sequencing depth. The anonymised identifiers indicate 
which samples belong to each patient, and which donor samples were used for each 
patient. 
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 Figure 5. Butyrate levels for the 2 donors (5 samples) and 7 patients (17 
samples consisting of 7 pre-FMT, 7 post-FMT and 3 follow-up samples). 
Patients were matched to a sample of either donor 5 (d5-s3, -s5, -s6 or –s7) or donor 
3 (d3-s2). High levels of butyrate characterised the donors (between 24 and 37 
mmol/kg) while the pre-FMT levels were disparate ranging from low (0) to high (21 
mmol/kg). The butyrate levels for most patients were found to have increased in the 
post-FMT and/or follow-up samples. The levels for patient R44 remained low 
(increasing from 0 at pre-FMT to 0.2 mmol/kg post-FMT). The P values are the 
results of Mann-Whitney t-tests between two groups of samples. 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Figure 6. Correlation map for selected metabolites and bacterial taxa. 
Metabolites and bacterial taxa were chosen based on having 0.5< | correlations | <1 
on the first axis of the sPLS canonical correlation analysis. 
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Table 1. Patient demographics.  
Patient 
code 
Gender Age 
(yrs) 
LoS post 
FMT 
(days) 
Bowel lavage 
administered? 
Donor 
sample 
Pre-FMT 
sample 
(days) 
Post-FMT 
sample 
(days) 
Documented 
Resolution of 
symptoms post-FMT 
Symptoms 
at 5 weeks 
Symptoms 
at 10 weeks 
Co-morbidities 
R48 Female 66 1 No D05-S3 9 141 1 day No No UC, HBP, 
diverticular 
disease 
R42 Female 63 1 Yes D05-S5 9 48 1 day No No NIDDM, liver 
cirrhosis, 
pancreatic 
insufficiency 
R44 Female 42 1 No D05-S6 8 11 1 day No No Alcohol abuse 
R05 Male 79 63 No D05-S6 1 30 No response due to 
concomitant 
carbapenem for HAP. 
n/a n/a Cancer, CKD4, 
NIDDM 
R23 Female 80 3 No D05-S7 2 23 2 days No No CKD4, renal 
dialysis, R.A, 
hypothyroidism  
R43 Male >90 43 
 
No D05-S7 2 21 8 days Relapse of 
symptoms 
Deceased CKD2, CCF 
R13 Male 78 6 No D03-S2 45 88 6 days No No Dementia, AKI  
AKI – acute kidney injury; CCF – congestive cardiac failure; CKD2 and CKD4 – chronic kidney disease stage 2 and 4; HAP – 
hospital-acquired pneumonia; HBP – high blood pressure; LoS – length of stay; NIDDM – noninsulin-dependent diabetes mellitus; 
R.A – rheumatoid arthritis; UC – ulcerative colitis. 
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Table 2. Median (± SD) relative abundance of bacterial taxa in which the largest 
proportional changes were observed across the different groups. 
 Including Patient R44 Excluding Patient R44 
Bacterial phyla 
Donor 
(%) 
Pre-FMT 
(%) 
Post-FMT 
(%) 
Follow-up 
FMT (%) 
Pre-FMT 
(%) 
Post-FMT 
(%) 
Follow-up 
FMT (%) 
Bacteroidetes 
15 
(±11) 
1.1 (±4) 6.5 (±18) 12.4 (±15.6) 1.5 (±4.2) 7.1 (±18.5) 12.4 (±15.6) 
Firmicutes 
78.5 
(±10.4) 
57.8 
(±17.4) 
50.3 
(±24.3) 
61.5 (±9) 
54.9 
(±18.6) 
51 (±14.6)  61.5 (±9) 
Proteobacteria 
1.1 
(±1.4) 
13.9 (±26) 
16.3 
(±36.6) 
3.6 (±9.4) 8.4 (±28.7) 1.5 (±18.4) 3.6 (±9.4) 
Bacterial genera        
Bacteroides 
14.7 
(±10.9) 
0.4 (±4.1) 4.6 (±17.3) 9.6 (±15.2) 0.7 (±4.4) 5.4 (±18) 9.6 (±15.2) 
Blautia 
23.14 
(±7.6) 
0.2 (±1.6) 3 (±10.2) 7.3 (±9.5) 0.3 (±1.7) 3.1 (±10.4) 7.3 (±9.5) 
Ruminococcus 
10.4 
(±7.5) 
1.6 (±4.3) 4.9 (±4.9) 11.1 (±6.4) 1.8 (±4.5) 5.8 (±4.8) 11.1 (±6.4) 
Enterococcus 
0.01 
(±0.1) 
11.3 (±12) 1.1 (±9.5) 0.4 (±4.1) 9.1 (±5.9) 0.2 (±10.5) 0.4 (±4.1) 
Escherichia 
0.1 
(±0.3) 
5.1 (±16.4) 3.5 (±12.9) 1.1 (±8.5) 6 (±17.3) 0.7 (±14.4) 1.1 (±8.5) 
Klebsiella 
0.01 
(±0) 
4.4 (±16) 0.2 (±34.4) 0.3 (±0.3) 3 (±17.7) 0.02 (±0.7) 0.3 (±0.3) 
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Table 3. Mean values (± SD) of 100 metabolites (mmol/kg) identified in faecal  
samples obtained from donors and patients.  
 
 mmol/kg 
Metabolite 
Index 
(ppm) Donors 
(n = 5) 
Pre-FMT 
(n = 7) 
Post-FMT 
(n = 7) 
Follow-up 
FMT 
(n = 3) 
Butyrate 0.89 30.25 (± 5.07) 5.39 (7.46) ** 7.67 (± 6.66) ** 17.67 (± 11.72) 
Acetate 1.90 108.44 (± 21.43) 49.94 (± 45.14) * 48.81 (± 33.81) * 126.04 (± 27.76) 
Propionate 1.05 13.20 (± 5.03) 12.46 (± 12.36) 10.57 (± 9.43) 26.92 (± 9.26) 
Valerate 0.87 1.58 (± 1.69) 0.78 (± 1.69) 0.87 (± 0.88) 1.93 (± 3.07) 
Isobutyrate 1.05 0.20 (± 0.34) 1.60 (± 2.14) 1.62 (± 2.05) 2.96 (± 2.47) 
Isocaproate 0.87 0 (± 0) 1.04 (± 2.09) 0.71 (± 1.43) 0.22 (± 0.39) 
Isovalerate 0.90 0.32 (± 0.44) 1.59 (± 1.97) 1.68 (± 1.45) * 2.84 (± 2.55) 
2-Methylbutyrate 0.85 0.10 (± 0.17) 0.77 (± 1.20) 0.63 (± 0.65) 1.16 (± 1.11) 
Lactate 1.33 1.98 (± 1.92) 1.23 (± 1.56) 7.73 (± 12.67) 16.08 (± 27.29) 
Lactaldehyde 1.37 0 (± 0) 0.08 (± 0.22) 0.15 (± 0.36) 0.56 (± 0.96) 
Formate 8.46 0.43 (± 0.62) 0.32 (± 0.60) 0.07 (± 0.04) 0.41 (± 0.53) 
1,2-propanediol 1.13 0.22 (± 0.15) 0.13 (± 0.08) 1.14 (± 2.68) 0.77 (± 1.29) 
Ethanol 1.17 5.86 (± 2.95) 1.07 (± 0.79) ** 1.92 (± 1.53) * 5.55 (± 8.45) 
Methanol 3.35 1.41 (± 0.36) 0.50 (± 0.97) * 0.25 (± 0.24) ** 0.55 (± 0.81) 
Ethylene glycol 3.70 1.87 (± 0.78) 1.27 (± 0.73) 0.98 (± 0.47) 1.10 (± 0.19) 
Glycerol 3.55 1.07 (± 1.10) 1.70 (± 1.77) 1.64 (± 2.64) 0.85 (± 0.49) 
Indole-3-lactate 7.50 0.01 (± 0.02) 0.01 (± 0.02) 0 (± 0) 0.03 (± 0.05) 
Indoleacetate 7.62 0 (± 0) 0.01 (± 0.01) 0 (± 0.01) 0.07 (± 0.12) 
Methylamine 2.59 0.57 (± 0.57) 0.16 (± 0.20) 0.17 (± 0.14) 0.33 (± 0.27) 
Dimethylamine 2.71 0.03 (± 0.03) 0.19 (± 0.17) 0.08 (± 0.14) 0.13 (± 0.11) 
Trimethylamine 2.89 0.24 (± 0.10) 0.29 (± 0.34) 0.24 (± 0.30) 0.35 (± 0.19) 
Putrescine 3.04 0.15 (± 0.12) 2.39 (± 2.67) 1.06 (± 1.19) 2.29 (± 2.05) 
Cadaverine 3.00 0.38 (± 0.52) 0.80 (± 1.33) 1.02 (± 0.74) 1.93 (± 1.00) 
Tyramine 7.21 0.10 (± 0.20) 0.27 (± 0.34) 0.30 (± 0.70) 0.10 (± 0.17) 
4-Hydroxyphenylacetate 6.85 0.05 (± 0.08) 0.21 (± 0.31) 0.53 (± 0.99) 1.94 (± 2.83) 
3-hydroxyphenylpropionate 6.74 0.17 (± 0.20) 0 (± 0.01) 0.01 (± 0.03) 0 (± 0) 
3-Hydroxyphenyl derivate 6.70 0.18 (± 0.18) 0 (± 0.01) 0.01 (± 0.02) 0.03 (± 0.06) 
3-Phenylpropionate 7.26 0.19 (± 0.17) 0.11 (± 0.15) 0.20 (± 0.24) 0.11 (± 0.10) 
Phenylacetate 7.29 0.08 (± 0.08) 0.79 (± 0.81) 0.62 (± 0.85) 1.00 (± 0.78) 
Phenylacetylglycine 7.35 0 (± 0) 0.04 (± 0.08) 0.03 (± 0.04) 0.02 (± 0.04) 
4-Aminohippurate 7.66 0 (± 0) 0.01 (± 0.01) 0.01 (± 0.02) 0.07 (± 0.12) 
p-Cresol 7.14 0 (± 0) 0.06 (± 0.08) 0.06 (± 0.09) 0.10 (± 0.18) 
Phenol 6.98 0 (± 0) 0.03 (± 0.05) 0.03 (± 0.05) 0 (± 0) 
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Benzoate 7.47 0 (± 0) 0.02 (± 0.05) 0 (± 0) 0.08 (± 0.14) 
2-Hydroxyisovalerate 0.82 0.02 (± 0.02) 0.19 (± 0.11) * 0.14 (± 0.13) 0.17 (± 0.17) 
3-Methyl-2-oxovalerate 1.09 1.14 (± 1.10) 2.81 (± 3.76) 1.45 (± 1.67) 3.55 (± 2.83) 
ɣ-aminobutyobetaine 3.12 1.76 (± 1.72) 2.69 (± 2.21) 2.82 (± 5.46) 4.02 (± 2.48) 
β-Alanine 2.55 0.45 (± 0.25) 0.28 (± 0.26) 0.41 (± 0.45) 1.07 (± 0.88) 
2-Aminoadipate 2.26 0 (± 0) 0 (± 0) 0.74 (± 1.65) 0 (± 0) 
2-Oxoisocaproate 0.92 0 (± 0) 0.07 (± 0.13) 0.01 (± 0.02) 0.02 (± 0.04) 
3-Aminoisobutanoate 1.18 0 (± 0) 0.65 (± 1.20) 1.89 (± 4.83) 0 (± 0) 
Methylsuccinate 1.09 0.24 (± 0.23) 0.08 (± 0.13) 0.06 (± 0.11) 0.22 (± 0.29) 
2-Piperidinone 3.28 0.17 (± 0.15) 0.01 (± 0.03) 0.15 (± 0.22) 0.26 (± 0.31) 
5-Aminopentanoate 2.22 2.45 (± 1.93) 5.71 (± 10.64) 1.51 (± 0.97) 1.19 (± 0.78) 
Acetaminophen 7.24 0 (± 0.01) 0.12 (± 0.15) 0.08 (± 0.09) 0.22 (± 0.39) 
Analgesic at 6.80 ppm 6.81 0 (± 0) 0.58 (± 1.53) 2.06 (± 5.42) 0 (± 0) 
Analgesic at 6.85 ppm 6.85 0 (± 0) 0.14 (± 0.37) 0.21 (± 0.57) 0 (± 0) 
Analgesic at 6.93 ppm 6.93 0 (± 0) 0.34 (± 0.91) 0.04 (± 0.06) 0.01 (± 0.02) 
Arabinose 4.51 0.62 (± 0.09) 0.24 (± 0.59) * 0.14 (± 0.18) ** 0.04 (± 0.06) * 
Fucose 4.54 0.23 (± 0.15) 0.01 (± 0.04) * 0.22 (± 0.23) 0.31 (± 0.32) 
Galactose 4.57 0.73 (± 0.19) 0.15 (± 0.16) ** 0.22 (± 0.18) ** 0.24 (± 0.17) * 
Glucose 4.64 8.12 (± 5.15) 3.95 (± 3.30) 10.97 (± 17.91) 5.70 (± 3.27) 
Ribose 4.92 0.70 (± 1.13) 0.59 (± 0.45) 0.55 (± 0.34) 1.64 (± 0.54) 
Alanine 1.47 3.58 (± 2.39) 5.21 (± 3.60) 5.32 (± 3.72) 7.25 (± 4.76) 
Asparagine 2.94 0.57 (± 0.16) 0.24 (± 0.25) 0.18 (± 0.26) 0.37 (± 0.64) 
Aspartate 2.80 1.66 (± 1.23) 0.87 (± 0.59) 1.00 (± 0.34) 2.00 (± 1.07) 
Glutamate 2.33 3.24 (± 2.90) 3.76 (± 4.81) 2.86 (± 2.57) 3.94 (± 2.76) 
Glutamine 2.46 2.37 (± 1.82) 0.59 (± 0.41) 0.73 (± 0.48) 1.24 (± 0.49) 
Glycine 3.54 2.21 (± 0.94) 5.79 (± 6.49) 2.92 (± 2.47) 2.74 (± 1.46) 
Histidine 7.05 0.37 (± 0.21) 0.62 (± 0.79) 0.62 (± 0.53) 0.57 (± 0.24) 
Isoleucine 1.00 1.00 (± 0.60) 1.47 (± 0.96) 1.31 (± 0.73) 1.91 (± 1.21) 
Methionine 2.63 0.47 (± 0.43) 0.57 (± 0.32) 0.80 (± 0.44) 1.25 (± 0.37) 
Valine 1.03 1.97 (± 1.15) 3.82 (± 2.39) 2.57 (± 2.04) 3.11 (± 1.67) 
Leucine 0.94 1.44 (± 0.90) 2.56 (± 1.44) 2.53 (± 1.22) 3.68 (± 1.32) 
Lysine 3.01 1.55 (± 0.10) 1.08 (± 0.11) 1.98 (± 0.13) 2.01 (± 0.06) 
Serine 3.84 0.89 (± 0.34) 1.27 (± 0.69) 1.24 (± 0.86) 2.60 (± 1.02) 
Threonine 4.25 1.07 (± 0.50) 0.58 (± 0.43) 1.15 (± 0.59) 2.16 (± 1.37) 
Phenylalanine 7.32 0.67 (± 0.35) 1.57 (± 1.05) 1.18 (± 0.61) 1.63 (± 0.41) 
Proline 4.12 0.48 (± 0.50) 1.55 (± 2.11) 0.90 (± 0.65) 0.96 (± 0.38) 
Pyroglutamate 2.50 0.10 (± 0.23) 0.12 (± 0.33) 0.07 (± 0.18) 0 (± 0) 
Tryptophan 7.73 0.18 (± 0.11) 0.39 (± 0.50) 0.30 (± 0.17) 0.38 (± 0.18) 
Tyrosine 7.18 0.85 (± 0.44) 1.01 (± 0.97) 1.04 (± 0.65) 1.65 (± 0.64) 
4-Aminobutyrate 2.27 0 (± 0) 0 (± 0) 0.42 (± 1.10) 0.94 (± 1.63) 
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Carnitine 3.22 0.02 (± 0.05) 0.38 (± 0.79) 0.05 (± 0.06) 0.02 (± 0.02) 
Taurine 3.25 0.95 (± 0.80) 1.06 (± 1.21) 0.38 (± 0.54) 0.35 (± 0.07) 
Choline 3.18 0.08 (± 0.07) 0.14 (± 0.18) 0.15 (± 0.15) 0.11 (± 0.08) 
Betaine 3.25 0 (± 0) 0 (± 0) 0.04 (± 0.11) 0 (± 0) 
Citrate 2.53 0.03 (± 0.05) 0.30 (± 0.42) 0.09 (± 0.10) 4.55 (± 7.33) 
Fumarate 6.51 0.05 (± 0.02) 0.05 (± 0.08) 0.03 (± 0.03) 0.05 (± 0.02) 
Succinate 2.39 21.85 (± 14.91) 8.80 (± 11.57) 9.79 (± 14.44) 9.23 (± 13.79) 
Pyruvate 1.46 0.63 (± 1.41) 1.17 (± 0.88) 0.23 (± 0.30) 0.49 (± 0.51) 
Creatine 3.02 0.23 (± 0.16) 1.02 (± 0.86) 0.13 (± 0.17) 0.24 (± 0.14) 
Creatinine 3.03 0.13 (± 0.15) 0.15 (± 0.22) 0.03 (± 0.05) 0.01 (± 0.02) 
3-Hydroxybutyrate 1.19 0.09 (± 0.12) 1.42 (± 3.67) 0.08 (± 0.22) 0 (± 0) 
Acylcarnitine 3.18 0.33 (± 0.26) 0.06 (± 0.10) 0.05 (± 0.05) 0.07 (± 0.06) 
Deoxycholate 0,71 0.35 (± 0.19) 0.10 (± 0.09) * 0.07 (± 0.13) * 0.10 (± 0.07) 
Lithocholate 0.66 0.84 (± 0.31) 0.29 (± 0.37) * 0.31 (± 0.35) * 0.37 (± 0.34) 
Cholate 0.71 0.52 (± 0.40) 0.14 (± 0.14) 0.37 (± 0.40) 0.24 (± 0.28) 
Adenine 8.10 0.07 (± 0.10) 0.08 (± 0.17) 0.03 (± 0.04) 0.02 (± 0.02) 
adenosine phosphate 8.60 0.03 (± 0.02) 0 (± 0.01) 0 (± 0) 0.01 (± 0.01) 
Hypoxanthine 8.18 0.17 (± 0.16) 0.09 (± 0.08) 0.18 (± 0.13) 0.27 (± 0.20) 
Inosine 6.09 0.02 (± 0.02) 0.01 (± 0.02) 0.01 (± 0.03) 0 (± 0.01) 
Uracil 5.79 0.23 (± 0.28) 0.29 (± 0.14) 0.29 (± 0.18) 0.71 (± 0.43) 
Uridine 5.89 0.03 (± 0.02) 0.01 (± 0.02) 0.03 (± 0.06) 0.04 (± 0.02) 
Xanthine 7.92 0.15 (± 0.09) 0.06 (± 0.06) 0.19 (± 0.29) 0.87 (± 1.41) 
Nicotinate 8.60 0.12 (± 0.12) 0.03 (± 0.03) 0.03 (± 0.03) 0.09 (± 0.01) 
NAD+ 9.32 <0.01 (± 0.01) 0 (± 0) 0 (± 0) 0 (± 0) 
Nicotinamide ribotide 9.58 0.05 (± 0.07) 0 (± 0) 0 (± 0) 0 (± 0) 
1-Methylnicotinamide 9.27 0 (± 0) 0.11 (± 0.29) 0 (± 0) 0 (± 0) 
Trigonelline 9.11 0 (± 0) 0.02 (± 0.05) 0 (± 0) 0.01 (± 0.01) 
The index in ppm indicates the chemical shifts of the most characteristic group of 
proton(s) for each metabolite. Mann-Whitney t-tests between two groups of samples 
(donors vs each of the other groups) * P < 0.05, ** P < 0.01 
 
